ticagrelor sandoz 90 mg film-coat. tabl.
sandoz sa-nv - ticagrelor 90 mg - film-coated tablet - 90 mg - ticagrelor 90 mg - ticagrelor
ticagrelor eg 60 mg film-coat. tabl.
eg sa-nv - ticagrelor 60 mg - film-coated tablet - 60 mg - ticagrelor 60 mg - ticagrelor
ticagrelor eg 90 mg film-coat. tabl.
eg sa-nv - ticagrelor 90 mg - film-coated tablet - 90 mg - ticagrelor 90 mg - ticagrelor
ticagrelor viatris 60 mg film-coat. tabl.
viatris gx bv-srl - ticagrelor 60 mg - film-coated tablet - 60 mg - ticagrelor 60 mg - ticagrelor
ticagrelor viatris 90 mg film-coat. tabl.
viatris gx bv-srl - ticagrelor 90 mg - film-coated tablet - 90 mg - ticagrelor 90 mg - ticagrelor
ticagrelor inovamed 60 mg
inovamed pharma ltd, israel - ticagrelor - film coated tablets - ticagrelor 60 mg - ticagrelor - ticagrelor inovamed , co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with - acute coronary syndromes (acs) or- a history of myocardial infarction (mi) and a high risk of developing an atherothrombotic event. limitations of use: 90 mg twice daily during the first year after an acs event followed by 60 mg twice daily for additional 2 years.
ticagrelor inovamed 90 mg
inovamed pharma ltd, israel - ticagrelor - film coated tablets - ticagrelor 90 mg - ticagrelor - ticagrelor inovamed , co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with - acute coronary syndromes (acs) or- a history of myocardial infarction (mi) and a high risk of developing an atherothrombotic event. limitations of use: 90 mg twice daily during the first year after an acs event followed by 60 mg twice daily for additional 2 years.
ticagrelor teva 60 mg
teva israel ltd - ticagrelor - film coated tablets - ticagrelor 60 mg - ticagrelor - ticagrelor teva, co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with - acute coronary syndromes (acs) or- a history of myocardial infarction (mi) and a high risk of developing an atherothrombotic event . limitations of use: 90 mg twice daily during the first year after an acs event followed by 60 mg twice daily for additional 2 years.
ticagrelor teva 90 mg
teva israel ltd - ticagrelor - film coated tablets - ticagrelor 90 mg - ticagrelor - ticagrelor teva, co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with - acute coronary syndromes (acs) or- a history of myocardial infarction (mi) and a high risk of developing an atherothrombotic event . limitations of use: 90 mg twice daily during the first year after an acs event followed by 60 mg twice daily for additional 2 years.
ticagrelor s.k. 60 mg
k.s.kim international (sk- pharma) ltd., israel - ticagrelor - film coated tablets - ticagrelor 60 mg - ticagrelor - ticagrelor s.k., co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with - acute coronary syndromes (acs) or- a history of myocardial infarction (mi) and a high risk of developing an atherothrombotic event.limitations of use: 90 mg twice daily during the first year after an acs event followed by 60 mg twice daily for additional 2 years.